Related Experiment Video
Updated: Aug 11, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results
Ella Achenbach1, David Lai1, Shiraj Sen1
1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
Abstract:
Soft tissue sarcomas are a heterogeneous group of rare malignancies with few effective standard therapies. Our understanding of the underlying biology driving tumorigenesis in these mesenchymal tumors have led to a growth in drug development for soft tissue sarcomas. This review focuses on novel targets in soft tissue sarcomas, describes early clinical trial results of drugs directed at these targets, and discusses the data surrounding the use of these compounds in clinical practice and rationale for possible future US Food and Drug Administration approvals.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Tumor Immunotherapy

